Table 5.

Patterns of hair loss among COVID-19 vaccinated individuals

Vaccine	Study group (n = 478)
	Acute TE	Exacerbated AGA	New onset A.A	Overlap AGA and TE	Recurrent A.A
Astrazeneca n = 164	139 (84.8%)	1 (0.6%)	12 (7.3%)	8 (4.9%)	4 (2.4%)
Johnson and Johnson n = 4	4 (100%)	0	0	0	0
Moderna n = 2	2 (100%)	0	0	0	0
Pfizer n = 12	4 (33.3%)	0	4 (33.3%)	4 (33.3%)	0
Sinopharm n = 116	96 (82.8%)	4 (3.4%)	8 (6.9%)	0	8 (6.9%)
Sinovac n = 92	72 (78.3%)	4 (4.3%)	12 (13.0%)	0	4 (4.3%)
Sputnik n = 68	52 (76.5%)	4 (5.9%)	4 (5.9%)	4 (5.9%)	4 (5.9%)
Sputnik light n = 20	20 (100.0%)	0	0	0	0
Total	389	13	40	16	20
Chi-square test	X2 = 74.7, P-value < 0.001

TE telogen effluvium, AGA androgentic alopecia, A.A alopecia areata

X²: chi-square test. P-value < 0.05 is considered significant